옵션 체인은 다양한 행사가격과 만기일에 대한 Coronado Global Resources의 주식 옵션 주요 데이터를 보여줍니다. 트레이더들은 이 정보를 사용하여 잠재적 거래를 분석하고 Coronado Global Resources에 대한 시장 심리를 평가합니다..

Coronado Global Resources (OTC:CODQL) 주식, 옵션 체인

Coronado Global Resources Inc is a producer, marketer, and exporter of a full range of metallurgical coals, an essential element in the production of steel. The Company has a portfolio of operating mines and development projects in Queensland, Australia and in the states of Pennsylvania, Virginia and West Virginia in the United States. It has two reportable segments being Australia and USA.

Bonds

Markets

CODQL

SCHW

TMUS

온라인 가구 소매업체인 웨이페어(NYSE:W)는 월요일 부채 일부를 상환하기 위해 7억 달러 규모의 보증부 채권을 발행한다고 발표했다. 이는 연방준비제도(연준)가 4년 만에 처음으로 금리를 인하한 지 일주일도 채 안 되어 다른 회사들의 채권 시장 진출에 합류한 것이다.

지난주 연준의 금리 인하 이후 기업들이 채권 시장으로 질주

Coronado Global Resources Inc hess Depository Interest

Coronado Global Resources Inc

HC Wainwright &amp; Co. analyst Yi Chen reiterates OPKO Health (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/OPK#NASDAQ">OPK</a>) with a Buy and maintains $3 price target.

News

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on OPKO Health, Maintains $3 Price Target

Shares of Dick&#8217;s Sporting Goods Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DKS#NYSE">DKS</a>) were under pressure in early trading on Wednesday, even after the company reported <a href="https://www.benzinga.com/24/12/42415162/dow-falls-150-points-oracle-posts-downbeat-results">upbeat fourth-quarter results</a>.
Here are some key analyst takeaways.
<ul>
<li>Stifel <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58beb7e7b85e93000190633d/jim-duffy">analyst Jim Duffy</a> maintained a Hold rating, while reducing the price target from $240 to $226.</li>
<li>Telsey Advisory Group <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5e301e08430dee0001c88c8d/joseph-feldman">analyst Joseph Feldman</a> reaffirmed an Outperform rating, while cutting the price target from $260 to $250.</li>
<li>Goldman Sachs <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/58580bcbee7bf60001bcfa29/kate-mcshane">analyst Kate McShane</a> reiterated a Buy rating, while reducing the price target from $280 to $242.</li>
<li>Wedbush <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/5846ee57ee7bf6000154d134/seth-basham">analyst Seth Basham</a> maintained a Neutral rating and price target of $215.</li>
<li>Guggenheim Securities <a href="https://www.benzinga.com/analyst-stock-ratings/analyst/585beadcb5a482000151d18b/keith-bachman">analyst Steven Forbes</a> reiterated a Neutral rating on the stock.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Stifel: Dick&#8217;s Sporting Goods' fourth-quarter net sales grew 6.4% to $3,894 million, beating Street expectations of $3,777 million, Duffy said in a note. The earnings beat was not as substantial, mainly due to below-the-line items, he added.
Management's earnings guidance for 2025 came in at a range of $13.80 to $14.40 per share, falling short of prevailing estimates, the analyst stated. "Increased inventory near-term supports potential comp upside in spring '25 but adds markdown risk should business slow," he further wrote.
Telsey Advisory Group: Dick&#8217;s Sporting Goods delivered another quarterly of "strong performance," with comps of 6.4% and earnings of $3.62 per share beating consensus of 3.1% and $3.52 per share, respectively, Feldman said. The company delivered a comp beat despite difficult comparisons and a relatively challenging consumer environment, he added.
In 2024, Dick&#8217;s Sporting Goods maintained its position as the largest US sporting goods retailer and grew its market share by around 50 basis points to about 9.0%, the analyst stated. The lower-than-expected earnings guidance for 2025 "mainly reflect investments in long-term strategic growth initiatives, weighing on near-term profitability," as the company is "accelerating growth of its new store concepts, House of Sport and Field House, which have been received well," he further wrote.
Goldman Sachs: Dick's Sporting Goods delivered a "solid" quarter, with healthy comps, margins and earnings, McShane said. The current momentum in the company's business, investments in digital and footwear as well as market share gains will support comps, she added.
Dick's Sporting Goods plans to continue growing its store concepts, including House of Sport, Field House, and Golf Galaxy Performance Center, the analyst stated. "We expect GameChanger and Dick's Media Network to remain important discussion points in FY25, which will serve as margin drivers and potentially result in multiple expansion over time," she further wrote.
Wedbush: Although Dick&#8217;s Sporting Goods' quarterly results "handily beat" consensus estimates, the 2025 comps and earnings guidance missed expectations, Basham said. The guidance came below consensus "even without including any impact from tariffs.&#8221;
Basham sees &#8220;more positives than negatives,&#8221; citing market share gains and strong gross margins supported by an assortment of premium products, strategic inventory investments, experiential retail concepts that are resonating, a strong eCommerce business, an impressive adjacent business in GameChanger and an emerging retail media network.
Guggenheim Securities: Dick's quarterly results "broadly exceeded our expectations," management&#8217;s 2025 outlook fell short, "with net capital expenditures needs ramping to over 7.0% of net sales," Forbes said.
The company&#8217;s "broad-based investment agenda" includes increasing square footage, technology investments and marketing expenses, the analyst stated. This indicates Dick Sporting Goods "is entering 2025 with an elevated breakeven comp profile.&#8221;
Price Action: Shares of Dick&#8217;s Sporting Goods had declined by 1.62% to $195.75 at the time of publication on Wednesday.
Read More: 
<ul>
<li><a href="https://www.benzinga.com/content/44189498/why-now-might-be-the-best-time-to-buy-target-stock">Why Now Might Be the Best Time to Buy Target Stock</a></li>
</ul>
Image: Shutterstock

Analyst Color

Earnings

Earnings Beats

Movers

Trading Ideas

Dick's Sporting Goods Posts Q4 Beat, Guidance Disappoints As Analysts Highlight Market Share Gains

Susquehanna analyst Mehdi Hosseini maintains Teradyne (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TER#NASDAQ">TER</a>) with a Positive and lowers the price target from $165 to $155.

Susquehanna Maintains Positive on Teradyne, Lowers Price Target to $155

RBC Capital analyst Douglas Miehm maintains Knight Therapeutics (TSX:<a class="ticker" href="https://www.benzinga.com/stock/GUD#TSX">GUD</a>) with a Outperform and raises the price target from C$7 to C$8.

TSX:GUD

RBC Capital Maintains Outperform on Knight Therapeutics, Raises Price Target to C$8

Susquehanna analyst Shyam Patil maintains JD.com (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JD#NASDAQ">JD</a>) with a Neutral and raises the price target from $35 to $45.

Susquehanna Maintains Neutral on JD.com, Raises Price Target to $45

RBC Capital analyst Paul Treiber maintains Enghouse Systems (TSX:<a class="ticker" href="https://www.benzinga.com/stock/ENGH#TSX">ENGH</a>) with a Outperform and lowers the price target from C$40 to C$38.

TSX:ENGH

RBC Capital Maintains Outperform on Enghouse Systems, Lowers Price Target to C$38

Susquehanna analyst Joseph Stauff upgrades Boyd Gaming (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BYD#NYSE">BYD</a>) from Neutral to Positive and lowers the price target from $79 to $77.

Upgrades

Susquehanna Upgrades Boyd Gaming to Positive, Lowers Price Target to $77

High-rolling investors have positioned themselves bullish on Viking Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VKTX#NASDAQ">VKTX</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in VKTX often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 8 options trades for Viking Therapeutics. This is not a typical pattern.
The sentiment among these major traders is split, with 37% bullish and 37% bearish. Among all the options we identified, there was one put, amounting to $25,535, and 7 calls, totaling $353,860.
<h3>What's The Price Target?</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $15.0 to $77.5 for Viking Therapeutics during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Viking Therapeutics stands at 531.67, with a total volume reaching 1,808.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Viking Therapeutics, situated within the strike price corridor from $15.0 to $77.5, throughout the last 30 days.
<h3>Viking Therapeutics 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741794336_0.png" alt="Options Call Chart" />
<h3>Noteworthy Options Activity:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>08/15/25</td>
<td>$9.8</td>
<td>$9.35</td>
<td>$9.6</td>
<td>$25.00</td>
<td>$96.0K</td>
<td>218</td>
<td align="right">101</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/04/25</td>
<td>$3.0</td>
<td>$1.89</td>
<td>$2.8</td>
<td>$30.00</td>
<td>$70.0K</td>
<td>534</td>
<td align="right">18</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.98</td>
<td>$1.32</td>
<td>$40.00</td>
<td>$44.4K</td>
<td>1.0K</td>
<td align="right">802</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/04/25</td>
<td>$3.9</td>
<td>$2.75</td>
<td>$2.98</td>
<td>$30.00</td>
<td>$44.4K</td>
<td>534</td>
<td align="right">376</td>
</tr>
<tr>
<td>VKTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$1.4</td>
<td>$0.97</td>
<td>$1.31</td>
<td>$40.00</td>
<td>$44.1K</td>
<td>1.0K</td>
<td align="right">465</td>
</tr>
</tbody>
</table>

<h3>About Viking Therapeutics</h3>
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
In light of the recent options history for Viking Therapeutics, it's now appropriate to focus on the company itself. We aim to explore its current performance.
<h3>Viking Therapeutics's Current Market Status</h3>
<ul>
<li>With a trading volume of 4,579,799, the price of VKTX is up by 8.18%, reaching $28.69.</li>
<li>Current RSI values indicate that the stock is may be approaching overbought.</li>
<li>Next earnings report is scheduled for 42 days from now.</li>
</ul>
<h3>Professional Analyst Ratings for Viking Therapeutics</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $102.0.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from Scotiabank has revised its rating downward to Sector Outperform, adjusting the price target to $102. 
&#x2A; In a cautious move, an analyst from HC Wainwright &amp; Co. downgraded its rating to Buy, setting a price target of $102. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Viking Therapeutics, <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> gives you real-time options trades alerts.

Options

VKTX

Behind the Scenes of Viking Therapeutics's Latest Options Trends

High-rolling investors have positioned themselves bullish on Cleveland-Cliffs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CLF#NYSE">CLF</a>), and it's important for retail traders to take note. 
\This activity came to our attention today through Benzinga's tracking of publicly available options data. The identities of these investors are uncertain, but such a significant move in CLF often signals that someone has privileged information.
Today, Benzinga's options scanner spotted 9 options trades for Cleveland-Cliffs. This is not a typical pattern.
The sentiment among these major traders is split, with 77% bullish and 11% bearish. Among all the options we identified, there was one put, amounting to $72,828, and 8 calls, totaling $315,324.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $7.0 and $20.0 for Cleveland-Cliffs, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Cleveland-Cliffs options trades today is 2623.0 with a total volume of 3,496.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Cleveland-Cliffs's big money trades within a strike price range of $7.0 to $20.0 over the last 30 days.
<h3>Cleveland-Cliffs Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741794331_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>04/11/25</td>
<td>$1.0</td>
<td>$0.97</td>
<td>$1.0</td>
<td>$9.50</td>
<td>$100.0K</td>
<td>108</td>
<td>1.0K</td>
</tr>
<tr>
<td>CLF</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$10.45</td>
<td>$10.4</td>
<td>$10.4</td>
<td>$20.00</td>
<td>$72.8K</td>
<td>2.7K</td>
<td>70</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>04/17/25</td>
<td>$0.42</td>
<td>$0.42</td>
<td>$0.42</td>
<td>$11.00</td>
<td>$42.0K</td>
<td>11.0K</td>
<td>1.3K</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/19/25</td>
<td>$1.21</td>
<td>$1.16</td>
<td>$1.16</td>
<td>$13.00</td>
<td>$32.9K</td>
<td>4.2K</td>
<td>334</td>
</tr>
<tr>
<td>CLF</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$3.1</td>
<td>$3.05</td>
<td>$3.1</td>
<td>$10.00</td>
<td>$31.0K</td>
<td>3.9K</td>
<td>112</td>
</tr>
</tbody>
</table>

<h3>About Cleveland-Cliffs</h3>
Cleveland-Cliffs Inc is a flat-rolled steel producer and manufacturer of iron ore pellets in North America. It is organized into four operating segments based on differentiated products, Steelmaking, Tubular, Tooling and Stamping and European Operations, but operates through one reportable segment -Steelmaking. It is vertically integrated from mined raw materials, direct reduced iron, and ferrous scrap to primary steelmaking and downstream finishing, stamping, tooling and tubing. It serves a diverse range of other markets due to its comprehensive offering of flat-rolled steel products. Geographically, it operates in the United States, Canada and other countries. The majority of revenue is from the United States. It is a supplier of steel to the automotive industry in North America.
After a thorough review of the options trading surrounding Cleveland-Cliffs, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Cleveland-Cliffs's Current Market Status</h3>
<ul>
<li>Currently trading with a volume of 13,423,034, the CLF's price is up by 7.26%, now at $9.68. </li>
<li>RSI readings suggest the stock is currently is currently neutral between overbought and oversold.</li>
<li>Anticipated earnings release is in 40 days.</li>
</ul>
<h3>What The Experts Say On Cleveland-Cliffs</h3>
2 market experts have recently issued ratings for this stock, with a consensus target price of $13.95.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; An analyst from GLJ Research persists with their Buy rating on Cleveland-Cliffs, maintaining a target price of $12. 
&#x2A; Maintaining their stance, an analyst from Goldman Sachs continues to hold a Buy rating for Cleveland-Cliffs, targeting a price of $15. 
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Cleveland-Cliffs options trades with real-time alerts from <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.

Check Out What Whales Are Doing With CLF

Whales with a lot of money to spend have taken a noticeably bullish stance on Hims &amp; Hers Health.
Looking at options history for Hims &amp; Hers Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>) we detected 16 trades.
If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and 37% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $210,245 and 12, calls, for a total amount of $1,400,840.
<h3>What's The Price Target?</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $15.0 to $43.0 for Hims &amp; Hers Health over the recent three months. 
<h3>Volume &amp; Open Interest Trends</h3>
Examining the volume and open interest provides crucial insights into stock research. This information is key in gauging liquidity and interest levels for Hims &amp; Hers Health's options at certain strike prices. Below, we present a snapshot of the trends in volume and open interest for calls and puts across Hims &amp; Hers Health's significant trades, within a strike price range of $15.0 to $43.0, over the past month.
<h3>Hims &amp; Hers Health Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741794326_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>05/16/25</td>
<td>$4.45</td>
<td>$4.1</td>
<td>$4.25</td>
<td>$38.00</td>
<td>$501.5K</td>
<td>2.0K</td>
<td>13</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$21.0</td>
<td>$20.7</td>
<td>$21.0</td>
<td>$15.00</td>
<td>$417.9K</td>
<td>3.2K</td>
<td>632</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>03/14/25</td>
<td>$1.25</td>
<td>$1.17</td>
<td>$1.25</td>
<td>$35.00</td>
<td>$112.3K</td>
<td>935</td>
<td>3.2K</td>
</tr>
<tr>
<td>HIMS</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>07/18/25</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$4.15</td>
<td>$27.00</td>
<td>$104.5K</td>
<td>969</td>
<td>254</td>
</tr>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$21.15</td>
<td>$21.0</td>
<td>$21.0</td>
<td>$15.00</td>
<td>$63.0K</td>
<td>3.2K</td>
<td>862</td>
</tr>
</tbody>
</table>

<h3>About Hims &amp; Hers Health</h3>
Hims &amp; Hers Health Inc is a multi-specialty telehealth platform that connects consumers to licensed healthcare professionals, enabling them to access high-quality medical care for numerous conditions related to mental health, sexual health, dermatology, haircare and more.
Following our analysis of the options activities associated with Hims &amp; Hers Health, we pivot to a closer look at the company's own performance.
<h3>Where Is Hims &amp; Hers Health Standing Right Now?</h3>
<ul>
<li>With a trading volume of 11,946,152, the price of HIMS is down by -1.33%, reaching $34.25.</li>
<li>Current RSI values indicate that the stock is is currently neutral between overbought and oversold.</li>
<li>Next earnings report is scheduled for 54 days from now.</li>
</ul>
<h3>What Analysts Are Saying About Hims &amp; Hers Health</h3>
A total of 5 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $33.8.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;adType=benzinga-insights&amp;ad=options-activity&amp;campaign=wallstreetadvantage">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from B of A Securities keeps a Underperform rating on Hims &amp; Hers Health with a target price of $21. 
&#x2A; In a cautious move, an analyst from Morgan Stanley downgraded its rating to Equal-Weight, setting a price target of $60. 
&#x2A; Maintaining their stance, an analyst from Leerink Partners continues to hold a Market Perform rating for Hims &amp; Hers Health, targeting a price of $40. 
&#x2A; An analyst from B of A Securities downgraded its action to Underperform with a price target of $21. 
&#x2A; In a cautious move, an analyst from Citigroup downgraded its rating to Sell, setting a price target of $27. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Hims &amp; Hers Health with <a href="https://www.benzinga.com/pro/">Benzinga Pro</a> for real-time alerts.

Hims & Hers Health, Inc. Class A Common Stock

HIMS

Check Out What Whales Are Doing With HIMS

RBC Capital analyst Conor McNamara maintains Illumina (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ILMN#NASDAQ">ILMN</a>) with a Outperform and lowers the price target from $247 to $128.

ILMN

RBC Capital Maintains Outperform on Illumina, Lowers Price Target to $128

Alibaba Group Holding (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BABA#NYSE">BABA</a>) is making waves in the AI space with its new artificial intelligence model, <a href="https://qwenlm.github.io/blog/qwq-32b/">QwQ-32B</a>. Developed by its AI unit, Qwen, this model has 32 billion parameters and claims performance comparable to DeepSeek's R1 model which has 671 billion parameters. This is in line with China's broader push to support key industries such as <a href="https://www.benzinga.com/news/25/02/43903135/ais-19-9-trillion-impact-could-create-the-first-trillionaire-but-mark-cuban-says-it-wont-be-musk-or-bezos">AI</a>, humanoid robots and 6G.
<h2 class="wp-block-heading">Alibaba's Big Bet on AI</h2>
After the QwQ-32B announcement, Alibaba's Hong Kong shares <a href="https://economictimes.indiatimes.com/markets/stocks/news/alibaba-shares-soar-74-in-2025-amid-the-latest-ai-bet-deepseek-rivalry-china-stocks-turning-a-corner/articleshow/118778507.cms?from=mdr">surged over 8%</a> and this year is up nearly 70%. As of March 9, the company's market cap is around $345 billion, according to Companies MarketCap. Alibaba's AI strategy is gaining traction.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/qnetic-2">This 12,000 RPM Spinning Battery With Over $100 Million In LOIs Could Be The Missing Link For Green Energy — Here&#8217;s Why Early Investors Are Flocking To Invest Before Funding Closes</a></li>
<li>BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a></li>
</ul>
According to <a href="https://qwenlm.github.io/blog/qwq-32b/">Qwen</a>, although QwQ-32B has fewer parameters than DeepSeek's R1, it excels in mathematical reasoning, coding and problem solving. This means operational cost savings and Alibaba is more competitive in the AI race. According to <a href="https://www.alibabacloud.com/blog/alibaba-cloud-teams-up-with-honor-zeekr-to-drive-ai-innovation-in-edge-devices_602046?spm=a2c65.11461447.0.0.39722486TOxjz4">Alibaba Cloud</a>, the company is also working with tech firms to put AI into consumer devices so its advancements can reach a broader audience.
Alibaba's top leaders have been meeting with Chinese government officials, including a meeting between President Xi Jinping and Jack Ma, Alibaba's co-founder. This level of engagement means strong government support for China's tech sector and its comeback.
Beijing's backing is a big reason for Alibaba's aggressive investment in AI. <a href="https://www.alibabacloud.com/blog/alibaba-to-invest-rmb380-billion-in-ai-and-cloud-infrastructure-over-next-three-years_602007">Alibaba Group announced</a> a plan to invest $53 billion for cloud computing and AI infrastructure. CEO Eddie Wu called AI a "once in a generation" opportunity that can replicate both intellectual and physical labor globally.
Trending: Dogecoin millionaires are increasing –<a href="https://www.benzinga.com/money/dogecoin-millionaires"> investors with $1M+ in DOGE revealed!</a>
Financially, Alibaba Cloud is reflecting this AI-first approach with 11% year-over-year revenue growth and AI related product revenue up triple digits for the sixth quarter in a row.
Alibaba is not alone in going all in on AI. According to <a href="https://www.digitaltrends.com/computing/amazon-to-spend-an-estimated-100-billion-ai-2025/">Digitaltrends</a>, Amazon Web Services is planning to spend around $100 billion next year, mostly on AI initiatives while Microsoft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>) is expected to <a href="https://blogs.microsoft.com/on-the-issues/2025/01/03/the-golden-opportunity-for-american-ai/">spend around $80 billion</a> with a big chunk on AI development. But experts are concerned.
Despite QwQ-32B&#8217;s efficiency, <a href="https://www.knowledgegpt.com/post/ai-language-models-reasoning-flaws-revealed">researchers</a> wonder if smaller models can manage the intricacies of the actual world just as effectively as larger models. Small models may struggle with tasks that require extensive contextual understanding, which larger models do better.
See Also: <a href="https://www.benzinga.com/money/gbr-savings-by-age">If You're Age 35, 50, or 60: Here&#8217;s How Much You Should Have Saved Vs. Invested By Now</a>
Alibaba's QwQ-32B is a big deal in AI, but as competition heats up and concerns grow the question is how do we make sure AI serves technological progress and societal well-being.
The rapid development of AI without ethics is raising big concerns of unintended consequences, including decision making bias and job displacement. According to <a href="https://www.theguardian.com/us-news/2025/mar/04/trump-ai-labor-protections">The Guardian</a>, recent rollbacks of AI-related labor protections in the US has made workers more vulnerable to automation <a href="https://www.benzinga.com/startups/25/02/43679965/klarnas-ceo-says-ai-can-already-do-all-the-jobs-that-we-as-humans-do-and-hes-proving-it-by-shrinking-his-workforce-by-22">job</a> losses and deteriorating employment conditions.
Experts warn that without proper regulations, companies will prioritise efficiency over human labor, perpetuating economic inequality and embedding biases into AI systems.
Read Next:
<ul>
<li>The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a></li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

BABA

MSFT

Jack Ma, Xi Jinping, And The $53B AI Bet—Alibaba's Comeback Signals A New Era For Chinese Big Tech

Keurig Dr Pepper (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/KDP#NASDAQ">KDP</a>) has outperformed the market over the past 15 years by 1.12% on an annualized basis producing an average annual return of 12.08%. Currently, Keurig Dr Pepper has a market capitalization of $44.53 billion. 
Buying $100 In KDP: If an investor had bought $100 of KDP stock 15 years ago, it would be worth $553.35 today based on a price of $32.82 for KDP at the time of writing.
<h3>Keurig Dr Pepper's Performance Over Last 15 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2025/1741794311_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In This Stock 15 Years Ago Would Be Worth This Much Today

<a href="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low" title="https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low">https://www.marijuanamoment.net/nevada-senators-take-up-resolution-calling-on-congress-to-reschedule-psychedelics-and-streamline-research/#:~:text=The%20resolution%20goes%20through%20research,reflects%20the%20therapeutic%20value%2C%20low</a>

Biotech

Legal

General

ATAI

CMND

CMPS

CYBN

DRUG

MIRA

MNMD

'Nevada Senators Take Up Resolution Calling On Congress To Reschedule Psychedelics And Streamline Research' - Marijuana Moment

RBC Capital analyst Mike Dahl maintains Ferguson Enterprises (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FERG#NYSE">FERG</a>) with a Outperform and lowers the price target from $211 to $189.

FERG

RBC Capital Maintains Outperform on Ferguson Enterprises, Lowers Price Target to $189

Barrington Research analyst Alexander Paris maintains SuRo Capital (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SSSS#NASDAQ">SSSS</a>) with a Outperform and maintains $8 price target.

SSSS

Barrington Research Maintains Outperform on SuRo Capital, Maintains $8 Price Target

<a href="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions" title="https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions">https://www.statnews.com/2025/03/12/telehealth-platforms-senators-crosshairs-over-relationship-with-eli-lilly-pfizer/#:~:text=The%20group%20of%20senators%20led,the%20ability%20to%20fill%20prescriptions</a>

'Telehealth Platforms In Senators' Crosshairs Over Relationship With Eli Lilly, Pfizer; In Letters, Lawmakers Question If Direct-To-Consumer Deals Could Influence Prescriptions' - STAT News

Macquarie analyst Tao Qiu maintains Brookdale Senior Living (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BKD#NYSE">BKD</a>) with a Outperform and maintains $8 price target.

Macquarie Maintains Outperform on Brookdale Senior Living, Maintains $8 Price Target

RBC Capital analyst Irene Nattel maintains Casey's General Stores (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CASY#NASDAQ">CASY</a>) with a Sector Perform and raises the price target from $430 to $438.

CASY

RBC Capital Maintains Sector Perform on Casey's General Stores, Raises Price Target to $438

<a href="https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox">https://www.niaid.nih.gov/news-events/tecovirimat-safe-ineffective-treatment-clade-ii-mpox</a>
The antiviral drug tecovirimat used without other antivirals did not reduce the time to clinical resolution of clade II mpox lesions or improve pain control among adults in an international clinical trial sponsored by the National Institutes of Health (NIH). The&nbsp;<a href="https://www.niaid.nih.gov/news-events/nih-study-finds-tecovirimat-was-safe-did-not-improve-mpox-resolution-or-pain">trial enrollment was stopped in late 2024</a> when an interim analysis showed that tecovirimat monotherapy was ineffective in the study population. Detailed results were presented at the 2025 Conference on Retroviruses and Opportunistic Infections (CROI) in San Francisco.

Comments

Coronado Global Resources

Coronado Global Resources (CODQL) 옵션

No option chain data available. Please try again later

뉴스

파트너 / 기고자

벤징가 글로벌